Table 1.
The current status of drug development related to eat me/Don't eat me signals and the progress of associated clinical trials in the future. "Don't eat me" signals are blocked by monospecific antibodies, small molecules, and peptides to promote macrophage phagocytosis.
| Clinical Trial(s) ID | Trial Phase | Target | Drug | Pathologies |
|---|---|---|---|---|
|
NCT04313881 NCT04778397 NCT05079230 NCT04788043 NCT04827576 NCT04958785 NCT04892446 NCT04854499 NCT04778410 NCT04541017 NCT04435691 NCT02953782 NCT02953509 NCT05169944 NCT04751383 |
III III III II II II II II II I + II I + II I + II I + II I I |
CD47 | Magrolimab | AML |
|
NCT05002127 NCT04675294 NCT04675333 NCT05167409 NCT04755244 NCT04417517 NCT05025800 NCT05027139 NCT03013218 |
II + III II II II I + II I + II I + II I + II I |
CD47 | Evorpacept (ALX148) | B cell non- Hodgkin lymphoma |
|
NCT04886271 NCT04445701 NCT03834948 NCT04445701 |
I + II I + II I + II I + II |
CD47 | AO-176 | Malignancies/multiple myeloma Advanced solid tumors, relapsed/refractory multiple myeloma |
|
NCT04900350 NCT04980885 NCT04349969 NCT04728334 |
I + II I + II I I |
CD47 | AK117 | AML/myelodysplastic syndrome, malignant neoplasm |
| NCT04097769 | I | CD47 | HX009 | Advanced solid tumors |
|
NCT04266301 NCT04823624 NCT04150029 NCT04878432 NCT03946670 NCT04812548 NCT04623216 NCT02608268 |
III II II II II II I + II I + II |
Tim4/3 | Sabatolimab | Cancers: advanced malignancies/lower risk myelodysplastic syndrome/AML/myelodysplastic syndromes |
|
NCT03680508 NCT0281763 NCT03307785 |
II I I |
Tim4/3 | TSR-022 | Advanced solid tumors/liver cancer/melanoma |
| NCT03099109 | I | Tim4/3 | LY3321367 | Advanced/refractory solid tumors |
|
NCT03824080 NCT03184571 NCT03654833 NCT03649321 NCT03965494 NCT02488408 |
II II II I + II I I |
Axl | Bemcentinib | Recurrent glioblastoma, advanced solid tumors, metastatic breast cancer, AML, non- small cell lung cancer, malignant mesothelioma, Non-small cell lung cancer |
| NCT01357395 | II | Axl | Amuvatinib | Small cell lung cancer |
| NCT01639508 | II | Axl | Cabozantini | Non-small cell lung cancer |
| NCT02729298 | I | Axl | TP-0903 | Advanced solid tumors |
| NCT05888701 | I | CD24 | anti-CD24 mAb | Mantle-cell Lymphoma (MCL), CLL |
| NCT04552704 | I + II | CD24 | CD24Fc | advanced solid tumors |
| NCT04060407 | I + II | CD24 | CD24Fc with ipilimumab and nivolumab | Metastatic Melanoma |
|
NCT04552704 NCT04095858 NCT04976699 NCT02663622 |
I + II III II |
CD24 | Efprezimod Alfa (CD24Fc, MK-7110) | Solid tumors, Graft-versus-host disease |